Chung-Han Lee
Overview
Explore the profile of Chung-Han Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
4158
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kotecha R, Knezevic A, Arora K, Bandlamudi C, Kuo F, Carlo M, et al.
Cancer
. 2023 Oct;
130(5):692-701.
PMID: 37864521
Introduction: Genetic ancestry (GA) refers to population hereditary patterns that contribute to phenotypic differences seen among race/ethnicity groups, and differences among GA groups may highlight unique biological determinants that add...
12.
Guercio B, Sarfaty M, Teo M, Ratna N, Duzgol C, Funt S, et al.
Clin Cancer Res
. 2023 Sep;
29(22):4586-4595.
PMID: 37682528
Purpose: Erdafitinib is the only FDA-approved targeted therapy for FGFR2/3-altered metastatic urothelial cancer. We characterized the genetic landscape of FGFR-altered urothelial carcinoma and real-world clinical outcomes with erdafitinib, including on-treatment...
13.
Albiges L, Gurney H, Atduev V, Suarez C, Climent M, Pook D, et al.
Lancet Oncol
. 2023 Jul;
24(8):881-891.
PMID: 37451291
Background: Immunotherapy-based combinations including pembrolizumab plus lenvatinib are the standard of care for patients with first-line clear-cell renal cell carcinoma, but these combinations are not well characterised in non-clear-cell renal...
14.
Tang C, Xie A, Liu E, Kuo F, Kim M, DiNatale R, et al.
Cell Metab
. 2023 Jul;
35(8):1424-1440.e5.
PMID: 37413991
Tumor cell phenotypes and anti-tumor immune responses are shaped by local metabolite availability, but intratumoral metabolite heterogeneity (IMH) and its phenotypic consequences remain poorly understood. To study IMH, we profiled...
15.
Hahn A, Kotecha R, Viscuse P, Pieretti A, Wiele A, Jonasch E, et al.
Eur Urol Focus
. 2023 Mar;
9(5):734-741.
PMID: 36863962
Background: Renal cell carcinoma (RCC) with sarcomatoid and/or rhabdoid (S/R) dedifferentiation is a highly aggressive tumor with a poor prognosis. Immune checkpoint therapy (ICT) has shown significant treatment efficacy in...
16.
McGregor B, Geynisman D, Burotto M, Suarez C, Bourlon M, Barata P, et al.
Eur Urol Oncol
. 2023 Feb;
6(3):339-348.
PMID: 36842942
Background: The comparative efficacy and health-related quality of life (HRQoL) outcomes of nivolumab plus cabozantinib versus pembrolizumab plus axitinib as first-line treatments for advanced renal cell carcinoma (aRCC) have not...
17.
Fitzgerald K, Motzer R, Lee C
Nat Rev Urol
. 2022 Nov;
20(3):179-193.
PMID: 36369389
Localized renal cell carcinoma (RCC) is primarily managed with nephrectomy, which is performed with curative intent. However, disease recurs in ~20% of patients. Treatment with adjuvant therapies is used after...
18.
Fitzgerald K, Duzgol C, Knezevic A, Shapnik N, Kotecha R, Aggen D, et al.
Eur Urol
. 2022 Nov;
83(3):195-199.
PMID: 36344318
Immunotherapy (IO)-based combinations used to treat metastatic clear cell renal cell carcinoma (ccRCC) include dual immune checkpoint inhibition with ipilimumab and nivolumab (IO/IO) and several combinations of vascular endothelial growth...
19.
Choueiri T, Kluger H, George S, Tykodi S, Kuzel T, Perets R, et al.
J Immunother Cancer
. 2022 Nov;
10(11).
PMID: 36328377
Background: The role and sequencing of combination immuno-oncology (IO) therapy following progression on or after first-line IO therapy has not been well-established. The Fast Real-time Assessment of Combination Therapies in...
20.
Ged Y, Sanchez A, Patil S, Knezevic A, Stein E, Petruzella S, et al.
Clin Cancer Res
. 2022 Oct;
28(23):5180-5189.
PMID: 36190538
Purpose: High body mass index (BMI) may lead to improved immune-checkpoint blockade (ICB) outcomes in metastatic clear cell renal cell carcinoma (mccRCC). However, BMI is a crude body size measure....